The company's technology has been proven to enhance the efficacy, reduce toxicity, and enable targeted tissue accumulation for both therapeutic and imaging agents, making it possible for healthcare professionals to deliver superior products for known targets. PharmaIN's programs include Refractory Ascites, Cancer Immunotherapy, and other proprietary peptide drugs for outpatient therapy.